The target audience for this conference is basic and translational scientists and clinicians, both senior and young investigators that want to have a broad overview and detailed knowledge of the most recent advances in the field of immunotherapy.

Topics to be covered: Immune checkpoints; Innate immune response; Microbioma; Immune cell therapies; Vaccines; Biomarkers of response to immunotherapy; Mechanisms of resistance to immunotherapy

Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest meeting focused on cancer immunotherapy research and development in Europe, CIMT invites international participants for high-level scientific exchange, collaboration, and education focused on cancer immunotherapy.

The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting showcases cutting-edge cancer science and medicine.

The Summit for Cancer Immunotherapy (Summit4CI) is the annual scientific meeting of BioCanRx - Canada’s Immunotherapy Network. Summit4CI brings together up to 350 leading scientists, clinicians, students and economists with representatives from industry, patient groups, charities and government. The conference explores the latest progress in cancer immunotherapy from scientific, clinical, industry and patient perspectives, through internationally recognized speakers, scientific presentations, poster sessions, panel discussions an Oxford-style debate and networking opportunities.

Hear directly from science and business stakeholders on the latest data impacting IO to fight a wider range of cancers.

Scientific Organizers: Christian U Blank, Stefani Spranger and Anna Christina Obenauf

Important Meeting Deadlines: Early Registration Deadline: Jan. 28, 2025; Poster Abstract Deadline: Feb. 20, 2025

This conference will assemble top experts in the field to address the unmet clinical needs, and discuss how immunotherapy can reach patient populations that currently do not benefit. The program will explore how to overcome barriers to immune cell entry into tumors, as well as insufficient activation of anti-tumor immune responses. In addition, diverse immune cell therapies will be covered, from T-cell based mainstays like TILs, gene-modified T cells, and CAR-T cells, to emerging modalities deploying innate immune cells like dendritic and NK cells. A major theme will focus on what we can learn from clinical failures with regards to improving the design immunotherapies, as well as how to strategically combine them with cellular therapies for optimal outcomes. This bedside to bench perspective will provide critical insight to drive scientific and clinical advances beyond current limitations.

The SITC Spring Scientific, Cellular Therapy for Solid Tumors, will address the recent advances in adoptive cellular therapy for solid tumors and rate-limiting challenges that impede bringing these novel therapies to patients in need. The program will feature in-depth discussions of the latest scientific insights and advances in the field and unique opportunities and unanswered questions in the areas of target antigen selection, product design, and therapeutic efficacy and safety.

To celebrate our 10-year edition, we have gathered leading expert in the field of immunology and immunotherapy from around the world who will share the groundbreaking discoveries made in their respective fields over the past decade. This will provide a platform for stimulating discussions and an opportunity for sharing their vision and unique insights for the next advances to come.

This intensive international spring course is designed to provide students, fellows, academics and professionals with the means to understand key concepts, cutting-edge advances in immunotherapy and engage with leaders in field.

The 3-day course will be online via Zoom and feature live interactions with Postdocs, Ph.D. students and junior faculty from four continents. Organizers: Precision Immunology Institute at the Icahn School of Medicine.

This new major conference will encompass the very best of basic, translational, and clinical research in immunology, inflammation and immunotherapies for cancer, including immuno-oncology (IO) drugs, inflammatory modulators, vaccines, and cellular therapies. The cutting-edge AACR IO 2025 program will appeal to a wide audience of basic scientists, translational researchers, clinical investigators, regulators, industry, investors, and lay press. A mix of keynote lectures, major symposia, spotlight sessions, educational sessions, special sessions, and poster sessions with exhibits will cover the spectrum of the IO field – including late-breaking clinical trials sessions highlighting new agents and IO combinations, and the results of practice-changing clinical trials.

The Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Network (SCION) Workshop is an intimate immunotherapy clinical trial development program, led by experts in the field who are equipped to help their assigned students navigate through the unique considerations that accompany immunotherapy treatments.

Tailored to early-to-mid career scientists and clinicians in the field of cancer immunotherapy working in academic, clinical, industry and government settings, this hybrid program provides the best in cancer immunotherapy education taught by leading experts in the field.

Winter School participants gain a deep understanding of the core principles of tumor immunology and cancer immunotherapy, and developing areas in the field including biomarker technology, validation and clinical integration, clinical trial design, data analysis and considerations for combination therapies.

Normal and pathological immune responses function across tissues that harbor unique metabolic, environmental, and cellular microenvironments. Therefore the mechanisms that recruit and activate leukocytes, define their interstitial function and survival, or promote their retention in particular tissues are crucial to understanding how to boost, redirect, or restrict immune responses across the spectrum of health and disease. While the topic of tissue specific immunity has been touched on in other meetings, this is the first conference to integrate discussion across diverse tissues and disease contexts. The program will cover how various tissues shape the immune responses that are generated within, while highlighting emerging technologies that are enabling advancements in this field.

CONFERENCE COCHAIRS:

Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Neta Erez, Tel Aviv University, Tel Aviv, Israel

Sergei I. Grivennikov, Cedars-Sinai Medical Center, Los Angeles, California

Ilaria Malanchi, The Francis Crick Institute, London, England

The Leipzig Immune ONcology (LION) Conference will focus on the latest developments in immune oncology and provide a forum for leading scientists, clinicians, and industry professionals to exchange ideas and discuss new findings in this exciting field. We invite you to submit your abstracts for oral and poster presentations at the conference. In addition to a stimulating scientific program, the conference will feature networking opportunities, including a welcome reception and poster sessions, as well as an industry exhibition showcasing the latest technologies and services related to cancer immunotherapy research. The LION Conference is organized by the Fraunhofer Institute for Cell Therapy and Immunology IZI and the University Hospital Leipzig. We are looking forward to welcoming you in Leipzig this November and to hearing about your latest research in immune oncology.

SITC 2024 provides a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. The Annual Meeting consists of cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for structured and informal discussions, including important networking opportunities. SITC 2024 also includes updates on major national and international initiatives from academia, government and industry, as well as important society projects.

The audience includes basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research as well as pharmacists and payers, who wish to learn more about cancer immunology and immunotherapy and its incorporation into current (and future) effective cancer treatment.

CONFERENCE COCHAIRS

Yvonne Y. Chen, University of California, Los Angeles, California

Sergio Quezeda, University College London (UCL) Cancer Institute, London, England

Robert D. Schreiber, Washington University School of Medicine of St. Louis, St. Louis, Missouri

Fernando Vidal-Vanaclocha, The George Washington University, Washington, D.C.

This meeting collaboration between the Association for Cancer Immunotherapy CIMT and the Champalimaud Foundation will address promising paths towards effective cellular treatment modalities for patients with solid cancer and discuss the boundaries of synthetically engineered immune cells. The meeting will also discuss the innovation gap between academic and small biotech driven research, and the challenges of safe, biologically, and clinically relevant phase I / II clinical trials.

The summit sessions will offer a patient-focused perspective on cell therapy possibilities by addressing the quality and nature of the “cellular product” as the starting material for cell therapy; patient-specific therapy and product development including molecular engineering; longevity and “fitness” of cell products after adoptive transfer, and mobilization of autologous anti-cancer directed T-cell responses.

ESMO 2024 will disseminate the latest cutting-edge data, provide high quality education and unparalleled networking opportunities for oncologists and other stakeholders from all around the world.

Come discuss the latest strides in the dynamic field of cancer immunotherapy. Join the leaders in cancer immunology as they unveil groundbreaking insights during plenary sessions and proffered talks curated from the abstract submissions.

Conference Co-Chairpersons

Elizabeth M. Jaffee, Johns Hopkins Medicine

Guido Kroemer, Gustave Roussy Cancer Center

Dana Pe’er, Memorial Sloan Kettering Cancer Center

Özlem Türeci, BioNTech

Arthur, Sandra and Sarah Irving together with the Mass General Cancer Center are excited to announce the third annual “Arthur and Sandra Irving Cancer Immunology Symposium” to be held on June 24-27, 2024. The Symposium will bring together about 15 accomplished faculty mentors who are excited to share their discoveries and research career experience in cancer immunology with approximately 45 promising young scientists (post-docs and starting PIs).

Deadline: Friday, January 5, 2024

The 2024 ASCO Annual Meeting Program will feature over 200 sessions complementing Dr. Lynn Schuchter’s Presidential theme: The Art and Science of Cancer Care: From Comfort to Cure.

With rapid change in the field of cancer immunotherapy, Frontiers in Cancer Immunotherapy 2024 aims to shed light on promising novel therapies for patients with cancer. While the field has seen many successes over the last few years, challenges remain in understanding the basic biology of some tumor types and in identifying targets for developing novel therapies.

This symposium presents a remarkable opportunity to convene with other researchers, clinicians, and industry leaders to discuss the extraordinary progress and immense potential of new drug therapies and technologies in paving the way for a brighter future in cancer treatment.

Welcome to Europe’s largest meeting focused on cancer immunotherapy research and development. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest meeting focused on cancer immunotherapy research and development in Europe, CIMT invites international participants for high-level scientific exchange, collaboration, and education focused on cancer immunotherapy.

This meeting will focus on myeloid cells with or without antigen presenting cell (APC) function, including dendritic cells, macrophages and monocyte-derived cells which have both the ability to shape the immune microenvironment of tumor lesions and instruct T cell effector and regulatory programs. The program will highlight the diversity of the tumor-associated APC compartment and describe its cellular and molecular composition and spatial distribution in tumor lesions.

A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in the discovery & development of cancer immunotherapies with dedicated sessions on different therapeutic modalities, biomarkers, precision and omics-based approaches in IO as well as case studies on innovative preclinical and translational tools.

With a comprehensive agenda encompassing four distinct yet related programs - Modulating the Tumour Microenvironment, Next Generation Cell-Based Immunotherapies, Bispecific and Multi-specific Antibody Therapeutics and Therapeutic Cancer Vaccines, the Summit promises to be a forum for the exchange of cutting-edge research, and a platform for collaboration among the global immuno-oncology community.

Highlights include a plenary keynote session featuring 2 distinguished speakers; engaging breakout discussions that bring peers together to chat about the most pressing or contentious topics; a balanced faculty of industry and academia speakers; posters showcasing innovative studies and an Exhibit Hall gathering the technology leaders in the IO space.

The NCI RNA Biology Initiative aims to facilitate the rapid exchange of information and expertise on the structure, function, biological roles, and therapeutic uses of RNA. Our goal is to foster synergistic interactions amongst NIH investigators and between NIH investigators and the larger scientific community. We anticipate that new insights into RNA biology and the development of innovative RNA-based tools and therapies will both define novel targets and accelerate the implementation of therapeutic interventions in cancer.

This one-day workshop will bring together leaders from industry, academia, and government with expertise in therapeutic oligonucleotides, delivery, small molecules, and preclinical development of novel RNA-based and RNA-targeted therapies.

"The thymus: from biology to medicine and back"

PROGRAM COMMITTEE CHAIRS

Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts
Christina Curtis, Stanford University, Stanford, California

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

More information about the AACR Annual Meeting 2024 will be available online and in the Call for Abstracts in late August 2023.

This conference will cover new scientific areas that bring together aspects of cancer biology and immunity that are often only discussed at separate specialized meetings. The presence of both basic and clinical investigators will expose the participants to these new concepts and provide an opportunity to discuss and explore the clinical translation of this rapidly emerging new understanding of cancer immunobiology.

Organizers: James Allison, Andrea Schietinger, Antoni Ribas, and Padmanee Sharma.

This meeting brings together scientists and clinicians from many aspects of tumor immunology to rethink the next steps in the evolution of cancer immunotherapy. It is expected to provide a springboard toward basic science discoveries and new, more effective therapies.

IMPORTANT DATES

Registration Site Opens: August 2023

Abstract Submission Site Opens: Sept. 15, 2023

Abstract Submission Site Closes: Jan. 10, 2024

Early Registration and Housing Deadline: Feb. 12, 2024

The 2024 Advanced Course in Basic & Clinical Immunology will be held February 4-February 7, 2024, in La Jolla, California. 16 course lectures from renowned faculty presented a clinical spin on major topics in cellular and molecular immunology.

The lectures, delivered by talented faculty who are renowned ability to span basic and clinical science, take attendees from the bench to the bedside and back again.

Via its small size with 24 early-career researchers, the Winter School is designed to offer participants an extraordinary development experience among peers and leaders in a beautiful setting. The relaxed, yet comprehensive program and involvement of supportive leaders in the field provide participants with one-on-one learning and networking opportunities.

Submit your application by October 23, 2023.

SCIENTIFIC PLANNING COMMITTEE

Mustafa Diken, Johannes Gutenberg University, Mainz, Germany
Marina Garassino, University of Chicago, Chicago, Illinois, USA
Nir Hacohen, Broad Institute of MIT and Harvard; Massachusetts General Hospital, Boston, Massachusetts, USA
Susan M. Kaech, The Salk Institute for Biological Studies, La Jolla, California, USA
Paola Nisticò, Regina Elena National Cancer Institute, Rome, Italy
Pamela S. Ohashi, University of Toronto, Toronto, ON, Canada
Catherine Sautès-Fridman, University Paris-Descartes, Paris, France
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Özlem Türeci, BioNTech SE, Mainz, Germany
Cassian Yee, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Laurence Zitvogel, Gustave Roussy Institute, Villejuif, France